(19)
(11) EP 1 507 558 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.02.2012 Bulletin 2012/07

(45) Mention of the grant of the patent:
17.08.2011 Bulletin 2011/33

(21) Application number: 03730064.7

(22) Date of filing: 16.05.2003
(51) International Patent Classification (IPC): 
A61K 45/06(2006.01)
 A61P 9/00(2006.01)
(86) International application number:
PCT/EP2003/005188
(87) International publication number:
WO 2003/097098 (27.11.2003 Gazette 2003/48)

(54)

PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC

PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN RENIN INHIBITOR, EINEN KALZIUMKANALBLOCKER UND EIN DIURETIKUM

COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE RENINE, UN AGENT DE BLOCAGE DU CANAL DU CALCIUM ET UN DIURETIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 17.05.2002 US 381546 P

(43) Date of publication of application:
23.02.2005 Bulletin 2005/08

(60) Divisional application:
10177741.5 / 2316488

(73) Proprietors:
  • Novartis Pharma AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • FELDMAN, David, Louis
    Teaneck, NJ 07666 (US)
  • WEBB, Randy, Lee
    Flemington, NJ 08822 (US)

(74) Representative: Ligibel, Jean-Marc 
Novartis AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
WO-A-02/40007
WO-A-92/10097
 WO-A-02/43807
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).